Given the often metastatic and tumour-initiating activity of CXCR4+ cancer cells, inclusion of anti-CXCR4 ADC as part of the therapy regimen might increase benefit, particularly in tumours sensitive to microtubule inhibitor agents. Here, CXCR4 is linked to neoplasm.